Skin Barrier Products Market, By Product Type (Foam Applicator, Spray, Wipes, Tapes & Strips, and Others), By Indication (Urinary or Fecal Incontinence, Ostomy Management, Medical Adhesive-related Skin Injury (MARSI), Moisture-Associated Skin Damage (MASD), and Others), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home-care Settings, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Apr 2024

Code : CMI4962

Pages :167

Formats :

Excel and PDF

Industry : Medical Devices

Skin Barrier Products MarketSize and Trends

Figure 1: Global Skin Barrier Products Market Share (%) Analysis, By Product Type

Skin Barrier Products Market By Product Type

The skin barrier products market is estimated to be valued at USD 1,592.5 Mn in 2024 and is expected to reach USD 2,200.5 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.

The increasing cases of incontinence is the major factor that is expected to drive the global skin barrier products market growth over the forecast period.

Impact of COVID-19 on Demand and Supply of Skin Barrier Products

The COVID-19 pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regard to the transportation and distribution of healthcare products.

Market- Trends

The COVID-19 caused significant disruption to the delivery of patient care across the globe, including ostomy management or stoma care.

The emerging prevalence of urinary or fecal incontinence is expected to drive the growth of the global skin barrier products market. For instance, according to the Journal of Urology, in clinical setting, urinary incontinence is frequently underreported and underdiagnosed. The prevalence of urinary incontinence in the U.S. was 53% from 2005 to 2016; 16% of women had mixed urinary incontinence, 26% had stress only, and 10% had urgency only. While urgency and mixed urinary incontinence were most common in women aged over 60 years, stress urinary incontinence was most common in women aged 40–59 years.